Sulfasalazine

Sulfasalazine is prescribed to treat:

• Rheumatoid arthritis and ulcerative colitis • Various related conditions in the immunology category • Associated symptoms and complications

It is an important medication that helps manage these conditions effectively.

Sulfasalazine (Azulfidine) is a conventional disease-modifying antirheumatic drug used for rheumatoid arthritis, ulcerative colitis, and psoriatic arthritis. It is an old drug with an unusual design: it was built to be split apart by gut bacteria, and that mechanism explains where it works.

Mechanism of Action

Sulfasalazine is two molecules joined by an azo bond: sulfapyridine, a sulfonamide antibiotic, and 5-aminosalicylic acid, an anti-inflammatory agent. The intact compound is poorly absorbed in the small intestine and travels largely unchanged to the colon.

There, colonic bacteria cleave the azo bond, releasing both components at the site of action. This was a deliberate design — a prodrug that uses the gut microbiome as its activation step, delivering anti-inflammatory drug to the colon rather than to the systemic circulation.

The two halves then do different things. In inflammatory bowel disease, the 5-ASA component acts locally on colonic mucosa and is the therapeutic moiety, working through inhibition of prostaglandin and leukotriene synthesis and reduction of inflammatory cytokines. In rheumatoid arthritis, the sulfapyridine component is thought to be responsible, acting systemically after absorption from the colon.

That division explains a practical point: the newer 5-ASA agents such as mesalamine deliver the anti-inflammatory half without the sulfapyridine, and they are consequently better tolerated in colitis — because most of sulfasalazine's side effects come from sulfapyridine. But they do not work in rheumatoid arthritis, where sulfapyridine is the active part.

Clinical Use

In rheumatoid arthritis, sulfasalazine is a conventional DMARD used where methotrexate is unsuitable or as part of combination therapy. It is less potent than methotrexate but has a reasonable safety profile and does not require the same monitoring intensity.

It has a specific advantage worth knowing: sulfasalazine is one of the few DMARDs considered acceptable in pregnancy, which makes it valuable in women with inflammatory arthritis who are pregnant or planning to be — a group for whom methotrexate is absolutely contraindicated.

In ulcerative colitis it is effective for inducing and maintaining remission in mild to moderate disease, though mesalamine has largely replaced it for tolerability. Sulfasalazine retains a role where there is coexisting arthritis, since it treats both.

Onset is slow, taking six to twelve weeks for full effect, and patients expecting quicker improvement stop prematurely. Dosing is titrated up gradually to limit gastrointestinal intolerance, which is the most common reason for discontinuation and is largely avoidable with slow escalation and enteric-coated formulations. Our musculoskeletal and gastrointestinal teams manage these regimens.

Monitoring and Follow-Up

Complete blood count and liver enzymes are checked at baseline, frequently during the first months, and periodically thereafter. Bone marrow suppression — leukopenia, agranulocytosis, and rarely aplastic anemia — is the serious hematologic risk and appears most often in the first few months.

Because agranulocytosis can develop between scheduled tests, patients should be told to report fever, sore throat, or mouth ulcers promptly rather than waiting for the next appointment.

Folate supplementation is standard, since sulfasalazine impairs folate absorption and can cause megaloblastic anemia. This is easy to overlook and is a straightforward preventable problem.

Hepatotoxicity occurs and warrants enzyme monitoring. Hypersensitivity reactions attributable to the sulfonamide component include rash, fever, and rarely severe cutaneous reactions including Stevens-Johnson syndrome — any rash warrants stopping and assessment rather than pushing through.

Two harmless effects should be mentioned in advance, because patients otherwise become alarmed: orange-yellow discolouration of urine, skin, and sweat, and permanent staining of soft contact lenses. Reversible oligospermia occurs in men, which matters for fertility and resolves on stopping. The MedlinePlus sulfasalazine entry covers prescribing detail, and the Crohn's and Colitis Foundation provides patient background.

Where sulfasalazine sits among the DMARDs is worth stating plainly. Methotrexate is more effective in rheumatoid arthritis and remains the anchor drug; hydroxychloroquine is better tolerated but less potent. Sulfasalazine occupies the middle, and the classic triple therapy combining all three has efficacy approaching that of a biologic at a fraction of the cost — a regimen that is under-used relative to its evidence, largely because the pill burden is unappealing and because biologics are more heavily promoted.

For a patient who cannot access or afford a biologic, or who prefers to exhaust conventional options first, triple therapy is a genuinely reasonable alternative rather than a consolation prize. It also avoids the infection screening, injection schedule, and malignancy surveillance that come with TNF inhibition.

Special Populations

In pregnancy, sulfasalazine is among the few DMARDs used, with high-dose folate supplementation recommended given the folate antagonism. It is generally compatible with breastfeeding in healthy term infants, though caution applies in premature or jaundiced infants.

In G6PD deficiency, the sulfonamide component can cause hemolysis. In true sulfonamide allergy it is contraindicated. In hepatic or renal impairment, caution and dose adjustment apply. In children it is used for juvenile idiopathic arthritis.

Sulfasalazine reduces absorption of digoxin and folic acid, and raises the risk of marrow suppression when combined with other myelosuppressive drugs. Slow acetylators reach higher sulfapyridine levels and experience more side effects, which is part of why tolerance varies so much between patients.

When to Contact Your Doctor

Report fever, sore throat, mouth ulcers, unusual bruising, or bleeding promptly — these may indicate marrow suppression and warrant a blood count without waiting for a scheduled test.

Stop the drug and seek assessment for any rash, particularly one that blisters or peels or occurs with fever. Report yellowing of the skin or eyes, dark urine, or persistent nausea with abdominal pain.

Report persistent nausea, abdominal discomfort, or headache, which are common early and often resolve with slower titration or an enteric-coated form rather than stopping altogether. Orange discolouration of urine and sweat is harmless and expected.

If you are planning pregnancy, raise it — sulfasalazine is one of the few options that can usually be continued.

To review your treatment, address side effects, or plan for pregnancy, contact us or schedule a visit.